Search Results - "Al-Rajabi R"

288eTiP A multicenter, open-label, first-in-human study of TYRA-430 in advanced hepatocellular carcinoma and other solid tumors with activating FGF/FGFR pathway aberrations (SURF431).

Authors: Goyal, L. Al-Rajabi, R. Sahin, I. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS318-S318. 1p.

Reply to the letter to the editor ‘A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma’ by Rosati et al.

Authors: Hines, R. B. Al-Rajabi, R.

Source: Annals of Oncology. May2016, Vol. 27 Issue 5, p957-958. 2p.

Prognostic impact of extra-nodal extension on colon and rectal cancer should be investigated separately.

Authors: Huang, Q. Yang, H. Hines, R. B. et al.

Source: Annals of Oncology. May2016, Vol. 27 Issue 5, p956-958. 3p.

SO-4 Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response.

Authors: Abou-Alfa, G. Sahai, V. Hollebecque, A. et al.

Source: Annals of Oncology. 2021 Supplement 3, Vol. 32, pS203-S204. 2p.

73PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study.

Authors: He, A R Weiss, G J Falchook, G et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study.

Authors: Cohen DJ Goldberg JD Leichman L et al.

Source: The oncologist [Oncologist] 2025 Oct 01; Vol. 30 (10).

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma.

Authors: Abou-Alfa GK Meyer T Do RKG et al.

Source: Liver cancer [Liver Cancer] 2024 Aug 08; Vol. 14 (1), pp. 58-67. Date of Electronic Publication: 2024 Aug 08 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: S. Karger Country of Publication: Switzerland NLM ID: 101597993 Publication Model: eCollection Cited Medium: Print ISSN: 2235-1795 (Print) Linking ISSN: 16645553 NLM ISO Abbreviation: Liver Cancer Subsets: PubMed not MEDLINE

Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.

Authors: Saeed A Park R Pathak H et al.

Source: Nature communications [Nat Commun] 2024 Feb 20; Vol. 15 (1), pp. 1533. Date of Electronic Publication: 2024 Feb 20.

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.

Authors: Kasi A Gaudel P Lekkala M et al.

Source: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2023 Dec; Vol. 29 (8), pp. 1951-1956. Date of Electronic Publication: 2023 Mar 07.

Publication Type: Journal Article

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-092X (Electronic) Linking ISSN: 10781552 NLM ISO Abbreviation: J Oncol Pharm Pract Subsets: MEDLINE

Doublecortin-like kinase 1 is a therapeutic target in squamous cell carcinoma.

Authors: Standing D Arnold L Dandawate P et al.

Source: Molecular carcinogenesis [Mol Carcinog] 2023 Feb; Vol. 62 (2), pp. 145-159. Date of Electronic Publication: 2022 Oct 11.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8811105 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-2744 (Electronic) Linking ISSN: 08991987 NLM ISO Abbreviation: Mol Carcinog Subsets: MEDLINE

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.

Authors: Vogel A Sahai V Hollebecque A et al.

Source: ESMO open [ESMO Open] 2024 Jun; Vol. 9 (6), pp. 103488. Date of Electronic Publication: 2024 Jun 04.

Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase II

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis.

Authors: Kasi A Abbasi S Handa S et al.

Source: JAMA network open [JAMA Netw Open] 2020 Dec 01; Vol. 3 (12), pp. e2030097. Date of Electronic Publication: 2020 Dec 01.

Publication Type: Journal Article; Meta-Analysis; Systematic Review

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients.

Authors: Freed IM Kasi A Fateru O et al.

Source: Cells [Cells] 2023 Sep 13; Vol. 12 (18). Date of Electronic Publication: 2023 Sep 13.

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE

A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.

Authors: Sun W Veeramachaneni N Al-Rajabi R et al.

Source: Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (15), pp. 16098-16107. Date of Electronic Publication: 2023 Jun 16.

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.

Authors: Mohyuddin GR Aziz M Britt A et al.

Source: BMC cancer [BMC Cancer] 2020 Jun 03; Vol. 20 (1), pp. 507. Date of Electronic Publication: 2020 Jun 03.

Publication Type: Comparative Study; Journal Article; Meta-Analysis; Systematic Review

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors.

Authors: Richardson GE Al-Rajabi R Uprety D et al.

Source: Cancers [Cancers (Basel)] 2023 Apr 29; Vol. 15 (9). Date of Electronic Publication: 2023 Apr 29.

Publication Type: Journal Article

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.

Authors: Saeed A Park R Dai J et al.

Source: Cell reports. Medicine [Cell Rep Med] 2023 Feb 21; Vol. 4 (2), pp. 100916. Date of Electronic Publication: 2023 Jan 25.

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE

Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.

Authors: Saeed A Park R Al-Jumayli M et al.

Source: Clinical colorectal cancer [Clin Colorectal Cancer] 2019 Jun; Vol. 18 (2), pp. 81-90. Date of Electronic Publication: 2019 Feb 27.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101120693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0674 (Electronic) Linking ISSN: 15330028 NLM ISO Abbreviation: Clin Colorectal Cancer Subsets: MEDLINE

Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant.

Authors: Khan QJ Bivona CR Martin GA et al.

Source: JAMA oncology [JAMA Oncol] 2022 Jul 01; Vol. 8 (7), pp. 1053-1058.

Publication Type: Journal Article; Observational Study; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.

Authors: Adenis A Kulkarni AS Girotto GC et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Feb 01; Vol. 40 (4), pp. 382-391. Date of Electronic Publication: 2021 Nov 03.

Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE